Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorAndre, T.
dc.contributor.authorAmonkar, M.
dc.contributor.authorNorquist, J.
dc.contributor.authorShiu, K-K.
dc.contributor.authorKim, T. W.
dc.contributor.authorJensen, B. V.
dc.contributor.authorJensen, L. H.
dc.contributor.authorPunt, C. J.
dc.contributor.authorSmith, D.
dc.contributor.authorGarcia-Carbonero, R.
dc.contributor.authorSevilla, I.
dc.contributor.authorde la Fouchardiere, C.
dc.contributor.authorRivera, F.
dc.contributor.authorElez, E.
dc.contributor.authorDiaz, L. A.
dc.contributor.authorYoshino, T.
dc.contributor.authorVan Cutsem, E.
dc.contributor.authorYang, P.
dc.contributor.authorFarooqui, M. Z. H.
dc.contributor.authorLe, D.
dc.contributor.authoraffiliation[Andre, T.] Hop St Antoine, Med Oncol, Paris, France
dc.contributor.authoraffiliation[Amonkar, M.] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
dc.contributor.authoraffiliation[Norquist, J.] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
dc.contributor.authoraffiliation[Yang, P.] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
dc.contributor.authoraffiliation[Farooqui, M. Z. H.] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
dc.contributor.authoraffiliation[Shiu, K-K.] NHS Fdn Trust, Med Oncol, Univ Coll Hosp, London, England
dc.contributor.authoraffiliation[Kim, T. W.] Asan Med Ctr, Oncol, Seoul, South Korea
dc.contributor.authoraffiliation[Jensen, B. V.] Herlev Gentofte Hosp, Med Oncol, Herlev, Denmark
dc.contributor.authoraffiliation[Jensen, L. H.] Univ Hosp Southern Denmark, Oncol, Vejle, Denmark
dc.contributor.authoraffiliation[Punt, C. J.] Acad Med Ctr, Med Oncol, Amsterdam, Netherlands
dc.contributor.authoraffiliation[Smith, D.] Hop Haut Leveque, Oncol, Pessac, France
dc.contributor.authoraffiliation[Garcia-Carbonero, R.] UCM, Hosp Univ 12 Octubre, Gastrointestinal Tumor Unit, Imas12, Madrid, Spain
dc.contributor.authoraffiliation[Sevilla, I.] Hosp Univ Reg & Virgen de la Victoria Malaga, Serv Oncol Invest Clin & Traslac Canc, Inst Invest Biomed Malaga IBIMA, Malaga, Spain
dc.contributor.authoraffiliation[de la Fouchardiere, C.] Ctr Leon Berard, Med Oncol, Lyon, France
dc.contributor.authoraffiliation[Rivera, F.] Hosp Univ M Valdecilla, Oncol, IDIVAL, Santander, Spain
dc.contributor.authoraffiliation[Elez, E.] Vall dHebron Inst Oncol, Gastrointestinal & Endocrine Tumors Grp, Barcelona, Spain
dc.contributor.authoraffiliation[Diaz, L. A.] Mem Sloan Kettering Canc Ctr, Solid Tumor Oncol, 1275 York Ave, New York, NY 10021 USA
dc.contributor.authoraffiliation[Yoshino, T.] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Onc, Kashiwa, Chiba, Japan
dc.contributor.authoraffiliation[Van Cutsem, E.] Univ Hosp Gasthuisberg Leuven, Digest Oncol, Leuven, Belgium
dc.contributor.authoraffiliation[Van Cutsem, E.] Katholieke Univ Leuven, Leuven, Belgium
dc.contributor.authoraffiliation[Le, D.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Oncol, Baltimore, MD USA
dc.contributor.funderMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
dc.date.accessioned2025-01-07T15:15:39Z
dc.date.available2025-01-07T15:15:39Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.507
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420405034/pdf
dc.identifier.urihttps://hdl.handle.net/10668/26993
dc.identifier.wosID573469100396
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.numberS409-S409
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleHealth-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía